Compassionate use of amphotericin B lipid complex (Abelcet) in life-threatening fungal infections: Report of 30 courses

Clinical Microbiology and Infection

Volumn 4, Issue 4, 1998, Pages 192-198

  Clevenbergh, Ph ^a,b   Jacobs, F ^a   Kentos, A ^a   Byl, B ^a   Collignon, L ^a   Moerman, M ^a   Serruys, E ^a   Thys, J P ^a  

^a ERASME HOSPITAL   (Belgium)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Amphotericin B lipid complex; Compassionate use; Tolerance

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CREATININE;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHILL; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPOTENSION; KIDNEY DISEASE; MALE; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0031900399     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1998.tb00668.x     Document Type: Article

References (12)

1. Khoo SH, Bond J, Denning DW. Administering amphotericin B-a practical approach. J Antimicrob Chemother 1994; 33: 203-13.
2. Sabra R, Branch R A. Amphotericin B nephrotoxicity. Drug Safety 1990; 5: 94-108.
3. Lopez-Berestein G, Bodey GP, Fainstein V, et al. Treatment of systemic fungal infections with liposornal amphotericin B. Arch Intern Med 1989; 149: 2533-6.
4. de Marie S, Janknegt R, Bakker-Woudenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B.J Antimicrob Chemother 1994; 33: 907-16.
5. Janknegt R, de Marie S, Bakker-Woudenberg I AJM and Crommelin DJA. Liposornal and lipid formulations of arnphotericn B. Clin Pharmacokinet 1992; 23: 279-91.
6. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991; 35: 615-21.
7. Lister J. Amphotericin B lipid complex (Abelcet®) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996; 56(suppl 57): 18-23.
8. Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997; 19: 343-7.
9. Kline S, Larsen TA, Fieber L, et al. Limited toxicity of prolonged therapy with very high doses of amphotericin B lipid complex. Clin Infect Dis 1995; 21: 1154-8.
10. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome®) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28(suppl B): 73-82.
11. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B therapy for invasive aspergillosis. Clin Infect Dis 1997; 24: 635-42.
12. Dismukes WE, Bennett JE, Drutz DJ, Graybill JR, Remington JS, Stevens DA. Criteria for evaluation of therapeutic response to antifungal drugs. Rev Infect Dis 1980; 2: 535-45.